profit from every $100 of sales.
$0$100
MoonLake Immunotherapeutics
$12.56-0.48% today
+16.1% in 1 year
1-year low $9.551-year high $22.16
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What MoonLake Immunotherapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$227 million of profit last year.
SalesProfit
MoonLake Immunotherapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| MoonLake Immunotherapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads MoonLake Immunotherapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -65 | -54 | -143 | -245 | |
| -65 | -44 | -120 | -220 | |
| -50 | -36 | -119 | -227 | |
| -1.28 | -0.73 | -1.89 | -3.53 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 77 | 527 | 478 | 424 |
| Cash | 40 | 451 | 180 | 335 |
| Total debt | 0 | 4 | 3 | 76 |
| Total liabilities | 8 | 13 | 25 | 120 |
| 49 | 496 | 447 | 304 | |
| 39 | 49 | 63 | 64 | |
| -104.5% | -7.0% | -21.3% | -46.2% | |
| -102.2% | -7.3% | -26.6% | -74.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -56 | -43 | -117 | -196 | |
| 0 | 0 | 1 | 0 | |
| -56 | -43 | -117 | -196 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 0 | – | |
| 10 | 7 | 7 | 13 |
Valuation
- –
- –
- –
- 4.9×
- –
- –
- –
- -18.3%
- -21.3%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -75.3%
- -358.8%
- -85.6%
- -64.2%
- -75.5%
- –
Growth
- –
- –
- −67.4%
- –
- +14.9%
Financial health
- 0.8×
- 0.40
- 25.2%
- -28.1×
- 8.60
- 8.60
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 2%of 952
Bottom 21%of 877
Bottom 4%of 988
What analysts expect
- Average price target
- $25.25
- Range
- $10.00 – $35.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.98 | -0.91 | −7.7% |
| Feb 25, 2026 | -0.92 | -0.92 | +0.0% |
| Nov 5, 2025 | -1.10 | -0.89 | −23.6% |
| Aug 5, 2025 | -0.87 | -0.73 | −19.2% |
| May 12, 2025 | -0.63 | -0.76 | +17.1% |
| Feb 26, 2025 | -0.72 | -0.53 | −35.8% |
| Nov 7, 2024 | -0.56 | -0.44 | −27.3% |
| Aug 7, 2024 | -0.39 | -0.28 | −39.3% |
News
MoonLake’s sonelokimab faces regulatory, commercial tests, RBC saysSeeking Alpha · Oct 18, 2026MoonLake Immunotherapeutics submits sonelokimab BLASeeking Alpha · Sep 30, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
20No pass
Benjamin Graham
37No pass
Philip Fisher
32No pass
Peter Lynch
53No pass
Joel Greenblatt
0No pass
Charlie Munger
36No pass
Terry Smith
37No pass
Questions about MoonLake Immunotherapeutics
Is MoonLake Immunotherapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the MoonLake Immunotherapeutics AI analysis
What does MoonLake Immunotherapeutics do?
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. It is in Biotechnology.
Does MoonLake Immunotherapeutics pay a dividend?
No. MoonLake Immunotherapeutics does not pay a dividend at the moment.
Is MoonLake Immunotherapeutics stock halal?
No. MoonLake Immunotherapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 37% of its market value, at or above the 33% limit. How we check
How has MoonLake Immunotherapeutics stock done over the past year?
Up 16.1% over the past twelve months, to $12.56. It traded between $9.55 and $22.16 and is 43.3% below its high.
Who are MoonLake Immunotherapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with MoonLake Immunotherapeutics's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.